Amrutanjan Health Care Limited has informed the Exchange about Investor Presentation
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Amrutanjan Health Care reported FY25 net sales of ₹451.82 Cr, up 7.26% YoY, with profit after tax rising 13.03% to ₹50.83 Cr. Q4 FY25 net sales grew 6.57% to ₹135.41 Cr, while PAT jumped 11.13% to ₹15.18 Cr. The pain management category grew 7% in Q4, and women's hygiene brand Comfy posted 18% growth, now contributing a quarter of company revenue. Operating margins expanded by 58 basis points during the year. Management announced a new ethical marketing division with 30 medical reps, plans to enter the US Amazon marketplace with its balm range, and aims to triple body pain category sales by FY28.
Positive for shareholders — steady revenue growth, double-digit profit growth, and margin expansion signal healthy business momentum. Forward-looking targets for Comfy (gross margins from 33% to 40% by Q4 FY26) and body pain category (3x by FY28) provide a clear growth runway. Short-term headwinds flagged in the ORS/Electro+ segment due to competitive pressure may cap upside in that division.